Search

Your search keyword '"Brekke, Jorunn"' showing total 18 results
Start Over Author "Brekke, Jorunn"
18 results on '"Brekke, Jorunn"'

3. En kvinne i 30-årenemed forvirring.

Author

SCHAUFEL, MARGRETHE AASE, GÄRTNER, FABIAN, LEIVDAL, BODIL KRISTIN, HAUG, SVEN ANDRÉ, BREKKE, JORUNN, STORSTEIN, ANETTE MARGRETHE, TVEITEN, ØYSTEIN VESTERLI, BØDTKER, JØRN EILERT, and FLØTTEN, ØYSTEIN

Published
2024
Full Text
View/download PDF

4. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival

Author

Rahman, Mohummad Aminur, Gras Navarro, Andrea, Brekke, Jorunn, Engelsen, Agnete, Bindesbøll, Christian, Sarowar, Shahin, Bahador, Marzieh, Bifulco, Ersilia, Goplen, Dorota, Waha, Andreas, Lie, Stein Atle, Gjertsen, Bjørn Tore, Selheim, Frode, Enger, Per Øyvind, Simonsen, Anne, and Chekenya, Martha

Published
2019
Full Text
View/download PDF

5. BORTEM-17: A phase IB/II single arm, multicentre study investigating the efficacy of sequential bortezomib and temozolomide in recurrent GBM with unmethylated MGMT promoter—The results of an interim analysis.

Author

Goplen, Dorota, primary, Rahman, Mohummad Aminur, additional, Brandal, Petter, additional, Solheim, Tora Skeidsvoll, additional, Brekke, Jorunn, additional, Arnesen, Victoria Smith, additional, Oltedal, Leif, additional, Simonsen, Anne, additional, Waha, Andreas, additional, Marienhagen, Kirsten, additional, Haasz, Judit, additional, Miletic, Hrvoje, additional, Lie, Stein Atle, additional, and Chekenya, Martha, additional

Published
2023
Full Text
View/download PDF

6. Investigating survival, quality of life and cognition in PROton versus photon therapy forIDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden

Author

Heggebø, Liv Cathrine, primary, Borgen, Ida Maria Henriksen, additional, Rylander, Hillevi, additional, Kiserud, Cecilie, additional, Nordenmark, Tonje Haug, additional, Hellebust, Taran Paulsen, additional, Evensen, Morten Egeberg, additional, Gustavsson, Magnus, additional, Ramberg, Christina, additional, Sprauten, Mette, additional, Magelssen, Henriette, additional, Blakstad, Hanne, additional, Moorthy, Janani, additional, Andersson, Karin, additional, Raunert, Ingela, additional, Henry, Thomas, additional, Moe, Cecilie, additional, Granlund, Carin, additional, Goplen, Dorota, additional, Brekke, Jorunn, additional, Johannessen, Tor-Christian Aase, additional, Solheim, Tora Skeidsvoll, additional, Marienhagen, Kirsten, additional, Humberset, Øyvind, additional, Bergström, Per, additional, Agrup, Måns, additional, Dahl, Ludvig, additional, Gubanski, Michael, additional, Gojon, Helene, additional, Brahme, Carl-Johan, additional, Rydén, Isabelle, additional, Jakola, Asgeir S, additional, Vik-Mo, Einar O, additional, Lie, Hanne C., additional, Asphaug, Lars, additional, Hervani, Maziar, additional, Kristensen, Ingrid, additional, Rueegg, Corina Silvia, additional, Olsen, Inge C, additional, Ledal, Rolf J, additional, Degsell, Eskil, additional, Werlenius, Katja, additional, Blomstrand, Malin, additional, and Brandal, Petter, additional

Published
2023
Full Text
View/download PDF

8. Arterial Thromboembolism in Cancer Patients Treated with Apixaban

Author

Larsen, Trine-Lise, primary, Brekke, Jorunn, additional, Garresori, Herish, additional, Frøen, Hege, additional, Jacobsen, Eva-Marie, additional, Torfoss, Dag, additional, Skuterud Wik, Hilde, additional, Enden, Tone Ronnaug, additional, Porojnicu, Alina Carmen, additional, Quist-Paulsen, Petter, additional, Velle, Elin, additional, Sandset, Per Morten, additional, Ree, Anne Hansen, additional, and Dahm, Anders E.A., additional

Published
2022
Full Text
View/download PDF

9. Abstract CT114: BORTEM-17 - phase IB/II single arm, non-randomized controlled multicenter study investigating whether sequential bortezomib and temozolomide is safe and effective in recurrent GBM with unmethylated MGMT promoter

Author

Goplen, Dorota, primary, Rahman, Mohummad Aminur, additional, Brekke, Jorunn, additional, Arnesen, Victoria, additional, Simonsen, Anne, additional, Waha, Andreas, additional, Marienhagen, Kirstin, additional, Oltedal, Leif, additional, Haasz, Judit, additional, Miletic, Hrvoje, additional, Solheim, Tora Skeidsvoll, additional, Brandal, Petter, additional, Lie, Stein Atle, additional, and Chekenya, Martha, additional

Published
2022
Full Text
View/download PDF

10. Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).

Author

Goplen, Dorota, primary, Rahman, Mohummad Aminur, additional, Brekke, Jorunn, additional, Arnesen, Victoria Smith, additional, Simonsen, Anne, additional, Waha, Andreas, additional, Marienhagen, Kirsten, additional, Oltedal, Leif, additional, Haasz, Judit, additional, Miletic, Hrvoje, additional, Solheim, Tora Skeidsvoll, additional, Brandal, Petter, additional, Lie, Stein Atle, additional, and Chekenya, Martha, additional

Published
2022
Full Text
View/download PDF

11. Low Dose Apixaban As Secondary Prophylaxis for Venous Thromboembolism in Cancer Patients, 30 Months Follow-up

Author

Hannevik, Trine-Lise, primary, Garresori, Herish, additional, Brekke, Jorunn, additional, Enden, Tone Ronnaug, additional, Froen, Hege, additional, Jacobsen, Eva-Marie, additional, Quist-Paulsen, Petter, additional, Porojnicu, Alina Carmen, additional, Ree, Anne Hansen, additional, Torfoss, Dag, additional, Velle, Elin, additional, Skuterud Wik, Hilde, additional, Ghanima, Waleed, additional, Sandset, Per Morten, additional, and Dahm, Anders EA, additional

Published
2021
Full Text
View/download PDF

12. Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism

Author

Hannevik, Trine-Lise, primary, Brekke, Jorunn, additional, Enden, Tone, additional, Frøen, Hege, additional, Garresori, Herish, additional, Jacobsen, Eva Marie, additional, Paulsen, Petter Quist, additional, Porojnicu, Alina Carmen, additional, Ree, Anne Hansen, additional, Torfoss, Dag, additional, Velle, Elin Osvik, additional, Wik, Hilde Skuterud, additional, Ghanima, Waleed, additional, Sandset, Per Morten, additional, and Dahm, Anders Erik Astrup, additional

Published
2020
Full Text
View/download PDF

13. Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study

Author

Rahman, Mohummad A., primary, Brekke, Jorunn, additional, Arnesen, Victoria, additional, Hannisdal, Marianne H., additional, Navarro, Andrea G., additional, Waha, Andreas, additional, Herfindal, Lars, additional, Rygh, Cecilie B., additional, Bratland, Eirik, additional, Brandal, Petter, additional, Haasz, Judit, additional, Oltedal, Leif, additional, Miletic, Hrvoje, additional, Lundervold, Arvid, additional, Lie, Stein A., additional, Goplen, Dorota, additional, and Chekenya, Martha, additional

Published
2020
Full Text
View/download PDF

15. Abstract 2928: Bortezomib sensitizes glioblastoma with unmethylatedMGMTpromoter to temozolomide-chemotherapy through MGMT depletion and abrogated autophagy flux

Author

Rahman, Mohummad A., primary, Navarro, Andrea G., additional, Brekke, Jorunn, additional, Bindesbøll, Christian, additional, Engelsen, Agnete, additional, Sarowar, Shahin, additional, Bahador, Marzieh, additional, Gjertsen, Bjørn T., additional, Goplen, Dorota, additional, Enger, Per Ø., additional, Selheim, Frode, additional, Simonsen, Anne, additional, and Chekenya, Martha, additional

Published
2018
Full Text
View/download PDF

16. Barnet er den Andre - Om pedagogens ansvar for barnet i lys av Levinas' etikk

Author

Brekke, Jorunn

Subjects
Social science: 200 [VDP]
Abstract

Denne artikkelen presenter en tolkning av Emmanuel Levinas' etikk og belyser pedagogens ansvar for barnet med vekt på kunnskapens rolle. Levinas stiller etikken i primærposisjon forut for subjektivitetens bevissthet, overveielser og valg. Ansvaret er uvalgt og grenseløst, umulig og nødvendig. Den Andre med sin ubegipelige, unike annerledeshet og sårbarhet, er bestemmende for ansvaret. I det vi tolker og forstår oss på den Andre, reduserer vi den Andres særegenhet til å være innenfor våre egne forestillinger. Den etiske bevegelsen søker ut av forestillingenes totaliteter i retningsbestemmelsen mot den Andre. Pedagogens teoretiske kunnskaper om barnet representerer noen særlig farer for selvtilstrekkelighetens lukking, men også muligheter for åpning og bevegelse.

Published
2015

17. A woman in her thirties with confusion.

Author

Schaufel MA, Gärtner F, Leivdal BK, Haug SA, Brekke J, Storstein AM, Tveiten ØV, Bødtker JE, and Fløtten Ø

Subjects
Humans, Female, Adult, Magnetic Resonance Imaging, Coercion, Tomography, X-Ray Computed, Confusion etiology, Lung Neoplasms pathology, Brain Neoplasms pathology, Brain Neoplasms diagnostic imaging, Carcinoma, Non-Small-Cell Lung pathology
Abstract

Background: Coercion is rare in cancer treatment. We present a case where a young woman received gamma knife radiosurgery and immunochemotherapy under compulsory institutional care., Case Presentation: A previously healthy patient in her thirties was admitted to hospital due to confusion, apathy, weight loss and sleep disturbance. She had difficulties expressing herself and spoke with considerable latency. A brain MRI revealed a tumour of 23 mm in the left-side centrum semiovale and perifocal oedema, while a CT scan showed a 5.6 cm tumour in the right upper lobe and enlarged mediastinal lymph nodes. She was diagnosed with non-small cell lung cancer, no actionable mutations, PD-L1 <75 %. When she did not wish to return to the hospital to undergo gamma knife radiosurgery, she was readmitted under a formal decision to use coercion, and remained under institutional care for over six months. Today she is fully recovered and has no cancer progression almost five years after diagnosis., Interpretation: This case report illustrates the challenges of brain metastases and use of coercion during cancer treatment, both for the patient and healthcare personnel. There is a need for thorough interdisciplinary discussions and to establish as early as possible a shared understanding of the intention and scope of the forced treatment.

Published
2024
Full Text
View/download PDF

18. Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH- mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden.

Author

Heggebø LC, Borgen IMH, Rylander H, Kiserud C, Nordenmark TH, Hellebust TP, Evensen ME, Gustavsson M, Ramberg C, Sprauten M, Magelssen H, Blakstad H, Moorthy J, Andersson K, Raunert I, Henry T, Moe C, Granlund C, Goplen D, Brekke J, Johannessen TA, Solheim TS, Marienhagen K, Humberset Ø, Bergström P, Agrup M, Dahl L, Gubanski M, Gojon H, Brahme CJ, Rydén I, Jakola AS, Vik-Mo EO, Lie HC, Asphaug L, Hervani M, Kristensen I, Rueegg CS, Olsen IC, Ledal RJ, Degsell E, Werlenius K, Blomstrand M, and Brandal P

Subjects
Humans, Cognition, Norway, Quality of Life, Randomized Controlled Trials as Topic, Sweden, Glioma genetics, Glioma radiotherapy, Protons
Abstract

Introduction: The use of proton therapy increases globally despite a lack of randomised controlled trials demonstrating its efficacy and safety. Proton therapy enables sparing of non-neoplastic tissue from radiation. This is principally beneficial and holds promise of reduced long-term side effects. However, the sparing of seemingly non-cancerous tissue is not necessarily positive for isocitrate dehydrogenase ( IDH )-mutated diffuse gliomas grade 2-3, which have a diffuse growth pattern. With their relatively good prognosis, yet incurable nature, therapy needs to be delicately balanced to achieve a maximal survival benefit combined with an optimised quality of life., Methods and Analysis: PRO-GLIO (PROton versus photon therapy in IDH -mutated diffuse grade 2 and 3 GLIOmas) is an open-label, multicentre, randomised phase III non-inferiority study. 224 patients aged 18-65 years with IDH -mutated diffuse gliomas grade 2-3 from Norway and Sweden will be randomised 1:1 to radiotherapy delivered with protons (experimental arm) or photons (standard arm). First intervention-free survival at 2 years is the primary endpoint. Key secondary endpoints are fatigue and cognitive impairment, both at 2 years. Additional secondary outcomes include several survival measures, health-related quality of life parameters and health economy endpoints., Ethics and Dissemination: To implement proton therapy as part of standard of care for patients with IDH -mutated diffuse gliomas grade 2-3, it should be deemed safe. With its randomised controlled design testing proton versus photon therapy, PRO-GLIO will provide important information for this patient population concerning safety, cognition, fatigue and other quality of life parameters. As proton therapy is considerably more costly than its photon counterpart, cost-effectiveness will also be evaluated. PRO-GLIO is approved by ethical committees in Norway (Regional Committee for Medical & Health Research Ethics) and Sweden (The Swedish Ethical Review Authority) and patient inclusion has commenced. Trial results will be published in international peer-reviewed journals, relevant conferences, national and international meetings and expert forums., Trial Registration Number: ClinicalTrials.gov Registry (NCT05190172)., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results